Therefore, treatment with MELK inhibitor could be a desirable anticancer strategy for tumors with enhanced activity in the PI3K/Akt/mTOR pathway, such as breast, lung, ovarian, and prostate cancers [32]. This evidence concerns the gene AKT1 and prostate cancer.